Skip to main content
TVGN logo

Tevogen Bio Holdings Inc. (TVGN) Stock Price & Analysis

Tevogen Bio Holdings Inc. (TVGN) — MoonshotScore 32/100 (Weak band), calculated Nov 22, 2026. Price $5.90 (-6.35%), as of the Nov 20, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$5.90 −$0.40 (-6.35%)

Tevogen Bio Holdings Inc. · TVGN · NASDAQ

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company specializing in the development of off-the-shelf precision T cell therapeutics.

Price as of Nov 20, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Tevogen Bio Holdings (TVGN)

Weak
Business Quality Average (52)
Financial Safety Fragile (6)
Valuation Bubble (5)
Growth Durability Compounding (82)
Momentum Slipping (38)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but a fragile balance sheet and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Compounding; Momentum: Slipping.

Earnings yield is the main valuation drag relative to sector peers.

  • EPS beat 5 of the last 7 reports
  • ROE 248.5% · current ratio 0.33 · earnings yield -94.1% · free-cash-flow yield -46.6%

Holding back: balance-sheet strain, a rich price

Helping: durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TVGN (58 recorded, newest six shown)
RecordedScoreBand
30Weak
30Weak
30Weak
33Weak
33Weak
33Weak

The score moved from 33 in the stored Nov 21, 2026 snapshot to 32 in the current publication computed Nov 22, 2026 (-1); the largest pillar moves were Financial Safety -18 and Momentum +4. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$5.90
Change on the day-6.35%
Shares traded on the day9.4K

Price & events

Other perspectives

Council score for Tevogen Bio Holdings (TVGN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Negative
Valuation Negative
Growth Durability Strong
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 22, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Tevogen Bio Holdings (TVGN), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Tevogen Bio Holdings Inc. (TVGN) is listed on NASDAQ. It employs 18 people.

2 · Latest results

What do the latest results show for Tevogen Bio Holdings (TVGN)?

Short answer · as of

Against analyst estimates the company has EPS beat 5 of the last 7 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Tevogen Bio Holdings (TVGN)?

Short answer · as of

The MoonshotScore pillars rate durable growth as strengths. What is holding it back is balance-sheet strain, a rich price. The distress and quality screens read Piotroski F 1. Trailing ratios: ROE 248.5% · current ratio 0.33 · earnings yield -94.1% · free-cash-flow yield -46.6%.

4 · What to check next?

What should you watch next at Tevogen Bio Holdings (TVGN)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $0.00 · EPS -10.14 · 0 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for TVGN.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Tevogen Bio Holdings compare with its peers?

Short answer

Tevogen Bio Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$64.63 Nov 20, 2026$16.3B98 5-pillar Nov 22, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$554.73 Nov 20, 2026$23.6B97 5-pillar Nov 22, 2026
argenx SE (ARGX) Same industry, near in market value$925.70 Nov 20, 2026$58.2B96 5-pillar Nov 22, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$252.73 Nov 20, 2026$16.6B96 5-pillar Nov 22, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$91.35 Nov 20, 2026$10.4B96 5-pillar Nov 22, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$920.69 Nov 20, 2026$95.2B95 5-pillar Nov 22, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$150.57 Nov 20, 2026$15.2B94 5-pillar Nov 22, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.67 Nov 20, 2026$11.4B92 5-pillar Nov 22, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$63.34 Nov 20, 2026$9.57B92 5-pillar Nov 22, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Same industry, near in market value$515.02 Nov 20, 2026$131B91 5-pillar Nov 22, 2026
Incyte Corporation (INCY) Same industry, near in market value$114.63 Nov 20, 2026$23.4B91 5-pillar Nov 22, 2026
Novo Nordisk A/S (NVO) Same industry, near in market value$37.82 Nov 20, 2026$167B87 5-pillar Nov 22, 2026
Tevogen Bio Holdings (TVGN) — this page$5.90—32

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$0.00
EPS estimate
$-10.14

Measured against a quoted price of $5.90 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 2, 2026

Transactions
15
Identified insiders
7
Purchases
0
Sales
0
Other transactions
15

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TVGN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TVGN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Tevogen Bio Holdings (TVGN)

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for TVGN?

TVGN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is TVGN a good stock to buy?

Stock Expert AI does not rate TVGN buy, sell or hold. Tevogen Bio Holdings Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the TVGN stock price today?

The last price recorded for Tevogen Bio Holdings Inc. (TVGN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for TVGN?

Tevogen Bio Holdings Inc. (TVGN) holds a MoonshotScore in the low range. The company is based in Warren, New Jersey. Not financial advice.

How frequently does TVGN data refresh on this page?

TVGN's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven TVGN's recent stock price performance?

Tevogen Bio Holdings Inc. (TVGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative T cell therapy platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider TVGN overvalued or undervalued right now?

Tevogen Bio Holdings Inc. (TVGN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of TVGN?

Fractional-share availability for Tevogen Bio Holdings Inc. (TVGN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

How can I track TVGN's earnings and financial reports?

Tevogen Bio Holdings Inc. (TVGN) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for TVGN earnings announcements.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 6 from Financial Modeling Prep (FMP), 6 with no recorded source and 3 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.